Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Lymphoma 3Leukemia, Myeloid, Chronic-Phase 2Leukemia, Myeloid, Acute 2Leukemia 2Hodgkin Disease 2Radiation Injuries 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasms, Plasma Cell 1Myelodysplastic Syndromes 1Multiple Myeloma 1Melanoma 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Large-Cell, Immunoblastic 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Leukemia-Lymphoma, Adult T-Cell 1Leukemia, T-Cell 1Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 1Leukemia, Myeloid, Accelerated Phase 1Leukemia, Lymphocytic, Chronic, B-Cell 1HTLV-I Infections 1Gliosarcoma 1Glioma 1Glioblastoma 1Diabetes Mellitus, Insulin-Dependent, 10 1Burkitt Lymphoma 1Blast Crisis 1

Interventions

mogamulizumab 4Lenalidomide 3Cyclophosphamide 3Alemtuzumab 2peginterferon alfa-2b 1fludarabine phosphate 1fludarabine 1etoposide phosphate 1cobomarsen 1belinostat 1Zidovudine 1Vincristine 1Raltegravir Potassium 1Prednisone 1Oxaliplatin 1Introns 1Interleukin-15 1Granulocyte Colony-Stimulating Factor 1Gemcitabine 1Etoposide 1Doxorubicin 1Dexamethasone 1Daclizumab 1Cytarabine 1Cisplatin 1Calcium Dobesilate 1Bortezomib 1B3(Fv)-PE38KDEL recombinant immunotoxin 110-propargyl-10-deazaaminopterin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Leukemia-Lymphoma, Adult T-Cell × Daclizumab × Clear all
NCT00001941 2012-08-20

Anti-Tac for Treatment of Leukemia

National Institutes of Health Clinical Center (CC)

Phase 1/2 Completed
34 enrolled 12 charts
LymphoidOther hematologic neoplasm

Diabetes Mellitus, Insulin-Dependent, 10, Leukemia, T-Cell, Leukemia-Lymphoma, Adult T-Cell, HTLV-I Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡